No products in the cart.
CARB-X to fund development of rapid diagnostic test for sepsis
CARB-X announced today that is awarding Tucson, Arizona–based Accelerate Diagnostics $578,000 to develop a diagnostic test for sepsis based on new fiber optic technology.
The award will help the company develop a compact instrument that uses Stimulated Raman Spectroscopy to identify bacteria from positive blood culture with minimal sample processing within 15 minutes. The technology, which is currently in the feasibility phase of development, has demonstrated high sensitivity and specificity and the ability to identify a wide range of bacterial pathogens.
Sepsis, which is the body’s overwhelming and life-threatening reaction to an infection, causes an estimated 11 million deaths each year. Quick diagnosis of the causative pathogen is considered critical for appropriate treatment.
Accelerate would be eligible for up $2.1 million in additional funds from CARB-X (the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) if the project meets certain milestones.
“Prompt diagnosis and treatment provide the best chance for reducing death rates and improving recovery from sepsis,” CARB-X Research and Development Chief Erin Duffy, PhD, said in a CARB-X press release. “Accelerate’s technology aims to speed up delivery of diagnostic test results which would help clinicians make treatment decisions in the first critical hours of illness.”
Since its launch in 2016, CARB-X has awarded more than $480 million in funding to support the development of antibiotics, vaccines, diagnostics, and other products focused on antibiotic-resistant bacteria.
Jun 8 CARB-X press release
GARDP announces funding from Japan for antibiotic development
The Global Antibiotic Research and Development Partnership (GARDP) announced yesterday that it has received additional funding from the Japanese government to support its efforts to fight antibiotic-resistant infections.
The 200 million yen (US $1.8 million) investment by the government of Japan, the second payment of a 1 billion yen (US $9 million) pledge to GARDP over 5 years, will be used to accelerate research and development into treatments for the antibiotic-resistant “priority pathogens” identified by the World Health Organization, and ensure that these treatments are used responsibly and are accessible to all who need them. The funding covers the period April 2021 to March 2002
“We would like to express our gratitude to the Government of Japan, through the Ministry of Health, Labour and Welfare, for its ongoing support and commitment to addressing the silent pandemic of drug-resistant infections,” GARDP Executive Director Manica Balasegaram, MRCP, MSc, said in a press release. “This funding signals Japan’s leadership in global health, and recognition that achieving the UN Sustainable Development Goals will require urgent action to deliver effective antibiotics, available for every person who needs them.”
Jun 7 GARDP press release